BusinessAgile Therapeutics Reports Third Quarter 2017 Financial ResultsBy Nasdaq OMXNov 6, 2017, 9:20 PM UTC
BusinessAgile Therapeutics to Host First Analyst Day on October 10, 2017By Nasdaq OMXOct 2, 2017, 11:30 AM UTC
BusinessAgile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive MedicineBy Nasdaq OMXSep 7, 2017, 11:50 AM UTC
BusinessAgile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®By Nasdaq OMXJun 27, 2017, 12:00 PM UTC
BusinessAgile Therapeutics Reports First Quarter 2017 Financial ResultsBy Nasdaq OMXMay 8, 2017, 8:11 PM UTC
BusinessAgile Therapeutics Announces Results of its Pre-Submission Meeting with FDABy Nasdaq OMXApr 11, 2017, 11:00 AM UTC
BusinessAgile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 ConferenceBy Nasdaq OMXMar 16, 2017, 8:30 PM UTC
